Tools
Stock profile

Quanterix Corp (QTRX)

QTRX · Latest close $2.07 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$2.07
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

Quanterix Corp (QTRX) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Latest close $2.07 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

First Eagle Investment Management — 1 tracked fund hold QTRX. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

WATERS CORP /DE/ (WAT) · Avantor, Inc. (AVTR) · BIO-RAD LABORATORIES, INC. (BIO) · AGILENT TECHNOLOGIES, INC. (A) · ILLUMINA, INC. (ILMN) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
First Eagle Investment Management0.02%2,753,165ADDED (+111.8%) Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -34.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

12.771.642024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding133 of 8,857 filers
Long-only filers among them132
Change vs 2026 Q1+10 net · 133 entered · 123 exited
Shares reported, all filers29,416,110
Reported value, all filers$126.1M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryLaboratory Analytical Instruments (SIC 3826)
Revenue · FY2025$138.9M
Net income · FY2025$-107.2M
Total assets · FY2025$418.8M
Shares outstanding47,293,065
Market cap (at latest close)$97.9M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.

Short interest

Shares short · Oct 15, 20264,678,542
Share of shares outstanding9.89%
Days to cover8.41

Shares short at recent settlements — Jul 31, 2026: 4.5M · Aug 14, 2026: 4.7M · Aug 31, 2026: 4.8M · Sep 15, 2026: 5.0M · Sep 30, 2026: 5.0M · Oct 15, 2026: 4.7M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 10K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jun 12, 2024LAURIE OLSONDirector20,915$378.1KJun 12, 2024SEC filing
Apr 1, 2024LAURIE OLSONDirector1,000$23.5KApr 1, 2024SEC filing
Feb 14, 2024LAURIE OLSONDirector1,500$36.5KFeb 14, 2024SEC filing
Jan 2, 2024LAURIE OLSONDirector1,000$26.9KJan 2, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jul 15, 2025SCHEDULE 13D/A-49.5% (close Jul 16, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jul 16, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Portolan Capital Management, LLCSC 13G/A1,899,3084.0%Jun 30, 2026SEC filing
Aug 6, 2026First Eagle Investment Management, LLCSC 13G2,753,1655.8%Jun 30, 2026SEC filing
May 15, 2026Ameriprise Financial, Inc.SC 13G/A3,542,3747.5%Mar 31, 2026SEC filing
May 15, 2026Portolan Capital Management, LLCSC 13G/A2,945,8236.2%Mar 31, 2026SEC filing
May 7, 2026Ameriprise Financial, Inc.SC 13G/A990,2242.1%Apr 30, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026Ameriprise Financial, Inc.SC 13G/A4,996,07310.7%Dec 31, 2025SEC filing
Nov 19, 2025Telegraph Hill Partners III, L.P.SC 13G2,504,6485.4%Sep 30, 2025SEC filing
Nov 14, 2025Ameriprise Financial, Inc.SC 13G/A4,243,5129.1%Sep 30, 2025SEC filing
Aug 13, 2025Portolan Capital Management, LLCSC 13G/A3,633,6229.4%Jun 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Laboratory Analytical Instruments (SIC 3826). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).

Federal contracts: $3.5M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$1.9M
FY2022$657.7K
FY2023$414.7K
FY2024$388.4K
FY2025$210.3K
FY2026$-59.0K

Largest awards collected

Award IDAgencyAmountStart
75N92020C00035Department of Health and Human Services$18.2MSep 29, 2020
36C24E21N0113Department of Veterans Affairs$436.5KJul 15, 2021
36C24824P0467Department of Veterans Affairs$251.9KDec 21, 2023
36C24E22N0135Department of Veterans Affairs$223.2KJul 15, 2022
75N95023P00394Department of Health and Human Services$198.0KJun 27, 2023

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Red Flags

· Earnings Manipulation Suspect (Beneish) — Beneish M-Score above -1.78

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Financial Restatement (8-K 4.02) — Last 3 years: a non-reliance / restatement filing (8-K Item 4.02)

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)

Key figures

· Earnings Manipulation Suspect (Beneish) — M-Score: -0.62 · Receivables index: 0.92 · Margin deterioration: 1.29 · Sales growth index: 1.01 · Accruals ratio: -7.1%

· Distress Risk (Altman Z″) — Z″-Score: -1.83 · Working capital / assets: 0.33 · Retained earnings / assets: -1.38 · EBIT / assets: -0.30 · Equity / liabilities: 2.40

· Financial Restatement (8-K 4.02) — Latest event: Nov 12, 2024 · Events in 3 yrs: 1

· Auditor Change (8-K 4.01) — Latest event: May 14, 2025 · Events in 2 yrs: 1

· Late Filings (NT) — Latest event: Nov 13, 2024 · Events in 2 yrs: 1 · Latest form: NT 10-Q

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2025 Q2, ranked #32 of 50.

Also held by the tracked funds that hold QTRX — ranked by lift, the co-holding pattern described in Methodology: WATERS CORP /DE/ (WAT) · Avantor, Inc. (AVTR) · BIO-RAD LABORATORIES, INC. (BIO) · AGILENT TECHNOLOGIES, INC. (A) · ILLUMINA, INC. (ILMN) · METTLER TOLEDO INTERNATIONAL INC/ (MTD) · BRUKER CORP (BRKR) · 908 Devices Inc. (MASS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 18, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Nov 9, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Aug 10, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

WATERS CORP /DE/ (WAT) · Track Record: how the signals scored · Practice timing on QTRX

One email a week: the week’s new filings and research. Subscribe free

← QSR  ·  QTTB →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.